Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514001 · ClinicalTrials.gov registry record · Phase 2
A Study of AMDX-2011P in Participants With Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by Amydis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06514001: Recruiting Phase 2 study of Alzheimer Disease, sponsored by Amydis.
NCT06514001 is a Phase 2 study of Alzheimer Disease that is actively recruiting participants, run by Amydis. The registered enrollment target is 25 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06514001, a Phase 2 study of Alzheimer Disease, is actively recruiting participants, sponsored by Amydis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Primary Outcome
Incidence, nature and severity of adverse events/serious adverse events (AEs/SAEs)
Conditions Studied
Interventions
- DRUG AMDX-2011P
Study Locations (1)
Arizona
- Associated Retina Consultants - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What NCT06514001 shows while recruiting
NCT06514001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which AMDX-2011P is the first listed.
NCT06514001 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06514001 about?
NCT06514001 is a clinical study titled "A Study of AMDX-2011P in Participants With Alzheimer's Disease". The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
What is the current status of trial NCT06514001?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-03-07. Estimated completion is 2026-10.
What conditions does trial NCT06514001 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06514001?
The interventions under investigation include: AMDX-2011P (DRUG).
Who is sponsoring clinical trial NCT06514001?
This trial is sponsored by Amydis, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514001 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06514001's enrollment target sits among peer trials
25 256th of 306 higher than 50 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI